Abstract
Objective: Data on changes in bone mineral density (BMD) from valproate (VPA) therapy are ambiguous and conflicting. Thus, the aim of this study was to systematically review the existing data and carry out a meta-analysis to investigate the effect of VPA as a monotherapy on BMD in people with epilepsy (PWE). Methods: We systematically searched PubMed, EMBASE, and MEDLINE for eligible studies. We calculated the standardized mean difference (SMD) with 95% confidence interval (CI) to investigate the statistical power of the association between VPA treatment and BMD. Results: Nineteen studies were included in this systematic review and meta-analysis. We found that BMD was lower in the VPA group than in the control group (SMD: -0.44; 95% CI: -0.65 to -0.22). A significant association was found in adult patients (SMD: -0.57; 95% CI: -0.88 to -0.26; $I^2 = 69.8%$) and pediatric patients (SMD: -0.32; 95% CI: -0.60 to -0.03; $I^2 = 67.8%$) by subgroup analysis. This study indicated that BMD was significantly lower in patients treated for more than 36 months than in controls (SMD: -0.52; 95% CI: -0.76 to -0.27; $I^2 = 61.8%$). However, a significant difference was not found between patients who were treated for less than 36 months and controls (SMD: -0.36; 95% CI: -0.72 to 0.01; $I^2 = 74.8%$). Conclusion and significance: The present study provided evidence that VPA treatment was significantly associated with BMD loss in PWE. Thus, for patients at a high risk of osteoporosis and fracture, especially for patients who need long-term treatment, VPA may not be a good choice.
Introduction
Epilepsy affects over 50 million people worldwide, and antiepileptic drugs (AEDs) are the primary tool for seizure control. While older "enzyme-inducing" AEDs (like carbamazepine) are well-known to interfere with bone metabolism and Vitamin D levels, the data on Valproate (VPA)—a "non-inducing" enzyme inhibitor—has been inconsistent. Previous studies offered conflicting results: some suggested VPA was bone-neutral, while others linked it to osteoporosis and increased fracture risk. This paper addresses this ambiguity by performing a rigorous meta-analysis to determine if VPA monotherapy truly impacts bone mineral density (BMD) and whether factors like age or treatment duration influence this risk.
Methods
The authors conducted a systematic review following PRISMA guidelines, searching major medical databases (PubMed, EMBASE, and MEDLINE) for studies published up to July 2009. Key methodological features included the use of the Standardized Mean Difference (SMD) to aggregate results across different measurement units and the assessment of study quality using the Newcastle-Ottawa Scale (NOS).
The meta-analysis synthesized data from 19 observational studies, encompassing a total of 1,272 individuals (601 in VPA groups and 671 in control groups). The studies spanned diverse geographic regions, including Turkey, Iran, Korea, Iraq, Syria, Australia, the USA, and Japan.
Results
The meta-analysis confirmed that VPA monotherapy is significantly associated with BMD loss. Patients on VPA had significantly lower BMD than controls, with an overall SMD of -0.44 (95% CI: -0.65 to -0.22).
Key Insights
- The 36-Month Threshold: A critical finding is the temporal aspect of bone loss. While patients treated for less than 36 months showed a downward trend in BMD, it was not statistically significant (SMD -0.36). However, those treated for more than 36 months showed a clear, significant reduction in bone density (SMD -0.52).
- Age-Agnostic Risk: Bone loss affected both pediatric (SMD: -0.32) and adult (SMD: -0.57) populations, though the effect size appeared slightly larger in adults.
- Mechanism Beyond Vitamin D: VPA might directly interfere with bone matrix proteins like collagen I and osteonectin, potentially rearranging the cytoskeleton of osteoblasts.
Discussion and Limitations
By focusing strictly on monotherapy, the study eliminates the "noise" of drug-drug interactions, providing a clearer picture of VPA’s specific toxicity to bone tissue. However, the authors acknowledge several limitations, including high heterogeneity ($I^2 > 60%$) due to differences in patient ethnicity, diet, and physical activity. The search was also limited to English-language publications, and a lack of granular data prevented subgroup analyses based on sex or specifically for elderly patients.
Conclusion
For patients at high risk for osteoporosis or those requiring decades of seizure control, VPA may require closer monitoring of bone health or a transition to bone-neutral alternatives. Future research should explore biochemical pathways and the efficacy of bone-protective therapies like calcium or Vitamin D supplementation.
Summary updated